ArticleTranslational cancer research2026
Micropeptide colorectal neoplasia differentially expressed (CRNDE) 84aa encoded by CRNDE elicits a T-cell immune response to breast cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The activation of anti-tumor immunity by tumor antigens is central to cancer immunotherapy. Cryptic peptides from non-coding regions represent potential antigens, with long non-coding RNAs (lncRNAs) emerging as a novel source of such peptides. This study aims to demonstrate that specific lncRNAs overexpressed in immunologically "cold" tumors-breast cancer, encode immunogenic peptides capable of activating anti-tumor immune responses. Methods: We identified elevated colorectal neoplasia differentially expressed (CRNDE) expression in breast cancer via database mining and polymerase chain reaction (PCR). Plasmid transfection and Western blot confirmed CRNDE peptide production. The immunogenicity of the peptide was assessed by enzyme-linked immunospot (ELISpot) and flow cytometry, while its ability to activate cytotoxic T lymphocytes (CTLs) was evaluated through flow cytometry and lactate dehydrogenase (LDH) release assays. Immunohistochemistry (IHC) and Western blot verified high expression of the CRNDE encodes an 84-amino acid peptide (CRNDE 84aa) peptide in breast cancer. Finally, patient-derived xenograft (PDX) models were used to validate Results: We demonstrated that lncRNA CRNDE 84aa. A predicted HLA-A*02:01-restricted epitope of CRNDE 84aa induced a specific human T-cell response. CTLs from a breast cancer patient recognized the CRNDE 84aa epitope (FIMELLYWL) and lysed HLA-A2-positive breast cancer cells expressing CRNDE 84aa. Furthermore, human CD8 Conclusions: CRNDE 84aa is highly expressed in breast cancer and functions as a tumor antigen that activates anti-tumor immunity. This study suggests that lncRNA-encoded peptides represent a viable source of tumor antigens for immunologically "cold" tumors such as breast cancer, highlighting their potential as novel targets for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.